Influence of headache pain intensity and frequency on migraine-related disability in chronic migraine patients treated with OnabotulinumtoxinA

Table 3 Logistic regression model for ≥50% MIDAS score reduction rate

	OR (95% CI)	P-value
Headache days/month reduction	0.944 (0.900–0.989)	0.016
Moderate-severe headache days/month reduction	0.981 (0.948–1.014)	0.259
≥ 50% headache days rate	0.863 (0.296–2.523)	0.785
≥ 50% moderate-severe headache days rate	0.811 (0.798–1.348)	0.635
Conversion to episodic migraine	1.014 (0.490–3.742)	0.976
≥ 50% pain intensity reduction	2.486 (1.422–4.392)	0.002
Acute treatment use (pills/month)	0.993 (0.982–1.001)	0.144
≥ 50% acute treatment reduction (pills/month)	0.848 (0.417–1.689)	0.644
Conversion to non-medication overuse	1.073 (0.392–2.591)	0.814

Odds Ratio estimated from logistic regression analysis of the clinical outcomes associated to disability improvement. In bold are statistically significant outcomes from the model. The accuracy of the model (95% CI) in the testing set (n = 77 patients) was 0.64 (0.62–0.75), kappa = 0.30 and p-value = 0.015. OR Odds-ratio, CI Confidence Interval

ISSN: 1129-2377